ESC/EAS Guidelines on the Management of Dyslipidaemias (TF33) - TF Members and Additional Contributors Relationship Type of relationship with industry Financial declaration with Industry A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Platelet inhibitionA - Direct Personal payment: Speaker
Suomen sivusto, jossa voit ostaa halvalla ja laadukas Viagra http://osta-apteekki.com/ toimitus kaikkialle maailmaan.
Yritti äskettäin viagra, se toimii erittäin tehokkaasti)) Ostaa Internetin kautta täällä propecia Myös ostaa levitra oikeudenkäynti, vaikutus on silmiinpistävää.
Labfirst.cn3.1 Storage and stability
mation on purchasing a license to this product for Cat. no. 114.41D
This product is stable until the expiry date stated on the label when stored unopened at 2-8°C. Store Rev. no. 006
opened vials at 2-8°C and avoid bacterial contami- nation. Keep Dynabeads in liquid suspension du- ring storage and al handling steps, as drying wil result in reduced performance. Resuspend well be- Dynabeads® Mouse pan B (B220)
3.2 Technical Support
For research use only
2. Transfer the desired volume of Dynabeads to a Please contact Invitrogen Dynal AS for further 3.7 Warranty
technical support (see contact details). The products are warranted to the original pur- 3. Add the same volume of PBS w/0.1 % BSA (or chaser only to conform to the quantity and con- 3.3 Warning and Limitations
tents stated on the vial and outer labels for the 4. Place the tube in a magnet for 1 min and dis- This product is for research use only. Not intended duration of the stated shelf life. Invitrogen Dynal's for any animal or human therapeutic or diagnostic obligation and the purchaser's exclusive remedy under this warranty is limited either to replace- 5. Remove the tube from the magnet and resus- use unless otherwise stated. Follow appropriate ment, at Invitrogen Dynal's expense, of any pro- pend the Dynabeads to the original volume laboratory guidelines. This product contains 0.02% ducts which shall be defective in manufacture, cytotoxic. Avoid pipetting by mouth! Sodium
and which shall be returned to Invitrogen Dynal, azide may react with lead and copper plumbing to transportation prepaid, or at Invitrogen Dynal's op- 2.3 Depletion or Positive Isolation of B220 2.2 Sample Preparation
form highly explosive metal azides. When dispo- tion, refund of the purchase price. Claims for mer- Mouse cells are generally obtained from spleen, sing through plumbing drains, flush with large vo- chandise damaged in transit must be submitted to thymus or lymph node, but other sources can also lumes of water to prevent azide build up. the carrier. This warranty shall not apply to any products which shall have been altered outside Material Safety Data Sheet (MSDS) is available at Please visit www.invitrogen.com/cellisolation and Invitrogen Dynal, nor shall it apply to any products follow our QuickLinks for recommended sample which have been subjected to misuse or mishand- 1. PRODUCT DESCRIPTION
ling. ALL OTHER WARRANTIES, EXPRESSED, IM- 3.4 Trademarks and Patents
PLIED OR STATUTORY, ARE HEREBY SPECIFICAL- 1.1 Intended Use
Dynal, Dynabeads®, Dynal and MPC™ are either LY EXCLUDED, INCLUDING BUT NOT LIMITED TO Isolation (1-3) or depletion (4,5) of murine B cells registered trademarks or trademarks of Invitrogen directly from spleen or lymph node cell suspen- • It is critical to keep the cell suspension
Dynal AS, Oslo, Norway. Any registration or trade- FOR A PARTICULAR PURPOSE. Invitrogen Dynal's sions or other samples containing B cells. For rapid and buffer cold (2-8°C) during incuba-
mark symbols used herein denote the registration maximum liability is limited in all events to the pri- and consistent results in protein or gene expres- tion and separation procedures, to pre-
status of trademarks in the United States.
ce of the products sold by Invitrogen Dynal. IN NO sion analysis, lyse the B cells while still attached to vent phagocytosis of Dynabeads.
Trademarks may or may not be registered in other the beads and directly process for further mole- • Bead-bound cells must be handled gent-
FOR ANY SPECIAL, INCIDENTAL OR CONSEQUEN- ly. Avoid excess pipetting.
TIAL DAMAGES. Some states do not allow limits on • PBS containing Ca2+ or Mg2+ is not re-
3.5 Intellectual Property Disclaimer
warranties, or on remedies for breach in certain 1.2 Principle of Isolation
Invitrogen Dynal will not be responsible for viola- transactions. In such states, the limits set forth Dynabeads are mixed with the cell sample in a • BSA can be replaced by HSA or FCS.
tions or patent infringements that may occur with tube. The Dynabeads will bind to the target cells Sodium citrate can be replaced by EDTA.
during a short incubation, and then the bead- 4. REFERENCES
• Follow the magnet recommendations to
3.6 Limited Use Label License
1. Giordia E et al. Modular usage of the HLA-DRA ensure a successful isolation.
Positive isolation – discard the supernatant and
No. 5: Invitrogen Technology – The purchase of promoter in extra-hematopoietic and hemato- use the bead-bound cells for downstream applica- this product conveys to the buyer the non-transfe- poietic cell types of transgenic mice. FEBS Table 1: Volume of Dynabeads added per 1 ml rable right to use the purchased amount of the Depletion – discard the bead-bound cells and use
sample. The volumes can be scaled up as required.
product and components of the product in re- 2. Zeytin H et al. Combination of a Poxvirus- the remaining, untouched cells for any application.
search conducted by the buyer (whether the buyer Based Vaccine with a Cyclooxygenase-2 Inhibi- Positive
is an academic or for-profit entity). The buyer can- tor (Celecoxib) Elicits antitumor Immunity and isolation
1.3 Description of Materials
not sell or otherwise transfer (a) this product (b) Long-Term Survival in CEA.Tg/MIN Mice. Can- its components or (c) materials made using this Dynabeads Mouse pan B (B220) are uniform, product or its components to a third party or superparamagnetic polystyrene beads (4.5 µm dia- 3. Liu et al. Sle1ab Mediates the Aberrant Acti- otherwise use this product or its components or meter) coated with a monoclonal antibody specific vation of STAT3 and Ras-ERK Signaling Path- materials made using this product or its compo- for the B220 antigen. B220 (also known as CD45R) ways in B Lymphocytes. The Journal of Immu- nents for Commercial Purposes. The buyer may is expressed on all B cells throughout develop- transfer information or materials made through the ment, from the early pro-B stage of B cel differen- use of this product to a scientific collaborator, pro- 4. Gardby E et al. Impaired CD40 - signalling in vided that such transfer is not for any commercial CD19-deficient mice selectively affects T2-de- Purpose, and that such collaborator agrees in wri- perdent isotype switching. Scand. J. Immunol.
2.3 Depletion or Positive Isolation of
ting (a) not to transfer such materials to any third 5 ml Dynabeads Mouse pan B (B220)
B positive Mouse Cells
party, and (b) to use such transferred materials 5. Bai YL et al. L-selectin-dependent lymphoid oc- 4 x 108 Dynabeads/ml in phosphate buffered sali- 1. Add the appropriate volume of Dynabeads to and/or information solely for research and not for cupancy is required to induce alloantigen-spe- ne (PBS), pH 7.4, with 0.1% bovine serum albumin the prepared sample (for volumes see table 1).
Commercial Purposes. Commercial Purposes means any activity by a party for consideration and 2. Incubate for 20 min (positive isolation) or 30 may include, but is not limited to: (1) use of the • The product will process up to 1 x 109 leu-
min (depletion) at 2 - 8°C with gentle tilting 6. Hare KJ et al. Induction of thymocyte positive product or its components in manufacturing; (2) cocytes (f.ex. splenocytes).
selection does not convey immediate resistan- use of the product or its components to provide a ce to negative selection. Immunology. 2002; 3. Place the tube in a magnet for 2 min. service, information, or data; (3) use of the pro- Additional Materials Required
4. For depletion, transfer supernatant to a new duct or its components for therapeutic, diagnostic • Magnet: (Dynal MPC™): See www.invitrogen.com/ 7. Hardy R et al. Resolution and Characterization or prophylactic purposes; or (4) resale of the pro- duct or its components, whether or not such pro- of Pro-B Pre-Pro-B Cel Stages in Normal Mouse 5. For positive isolation, discard the supernatant duct or its components are resold for use in re- and wash the bead-bound cells 3 times by re- • Mixer allowing both tilting and rotation.
search. Invitrogen Corporation will not assert a suspending in PBS to the original sample volu- claim against the buyer of infringement of patents • PBS w/0.1% BSA: PBS pH 7.4 (without Ca2+ and owned or controlled by Invitrogen Corporation For molecular studies, lyse cells while still attached which cover this product based upon the manufac- Invitrogen Dynal is a part of the Invitrogen Group.
• Recommended culture media: RPMI 1640 or to the beads and transfer supernatant to a new ture, use or sale of a therapeutic, clinical diagnos- tic, vaccine or prophylactic product developed in tube for further mRNA, protein or other subcellular Contact details for your local Invitrogen sales
research by the buyer in which this product or its office/technical support can be found at
components was employed, provided that neither http://www.invitrogen.com/contact
this product nor any of its components was used in 2.1 Dynabeads Washing Procedure
3 GENERAL INFORMATION
the manufacture of such product. If the purchaser Copyright 2006 Invitrogen Dynal AS, Oslo, Norway.
Dynabeads should be washed before use.
Invitrogen Dynal AS complies with the Quality is not willing to accept the limitations of this limi- 1. Resuspend the Dynabeads in the vial.
ted use statement, Invitrogen is willing to accept return of the product with a full refund. For infor-
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
The Ne w E n g l a nd Jo u r n a l o f Me d ic i ne COMPARISON OF UPPER GASTROINTESTINAL TOXICITY OF ROFECOXIB AND NAPROXEN IN PATIENTS WITH RHEUMATOID ARTHRITIS CLAIRE BOMBARDIER, M.D., LOREN LAINE, M.D., ALISE REICIN, M.D., DEBORAH SHAPIRO, DR.P.H., RUBEN BURGOS-VARGAS, M.D., BARRY DAVIS, M.D., PH.D., RICHARD DAY, M.D., MARCOS BOSI FERRAZ, M.D., PH.D., CHRISTOPHER